NCT02071095 - Enhancement by Poly-ICLC During HIV-1 Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

July 26, 2016

Study Completion Date

July 26, 2016

Conditions

HIV-1 Infected Adults With Chronic HIV-1 Infection

Interventions

DRUG

Arm A: Poly-ICLC

Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.

DRUG

Arm B: Normal Saline

Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.

Trial Locations (1)

10065

The Rockefeller University Hospital, New York